Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: A prospective randomized controlled trial.

Cancer Med · 2019 · PMC6912063 · PMID 31663690

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significanceP = .08so close (0.05 < p ≤ 0.1)

In the control group, although the %EdU+ rate increased when cells were treated with postoperative serum compared with preoperative serum, the difference did not reach statistical significance (1.00 ± 0.07 precontrol vs 1.08 ± 0.20 postcontrol, P = .08).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.